NRAS and melanoma: For instance, pan-RAF inhibitor LXH254 blocks dimeric BRAF and CRAF, which can provide a potential clinical strategy when combined with MEK or ERK inhibitors to treat KRAS mutant NSCLC or NRAS mutant melanoma [38].